Please login to the form below

Not currently logged in
Email:
Password:

Medicines Discovery Catapult appoints CEO

Chris Molloy will take up the lead role in November this year

MDC Chris MolloyThe Alderley Park, Cheshire-based Medicines Discovery Catapult (MDC) has appointed Chris Molloy as its first ever chief executive officer.

Currently chief executive of life sciences recruitment firm The RSA Group, Molloy will take up the lead role at the recently-established MDC in November this year.

As chief executive, he will primarily work with the board of directors and government organisation Innovate UK to develop and implement a new five-year business plan for the drug discovery and early development firm.

Chairman Professor Graham Boulnois, said: “We are delighted to bring Chris on board as we start out exciting journey at the Medicines Discovery Catapult.

“Chris' experience of leading companies operating in life sciences combined with his in-depth knowledge of drug discovery will be of tremendous value to the company.”

Molloy moves to the MDC from The RSA Group, which he joined in 2009 as a non-executive director before becoming chief executive in 2013.

Prior to this, he has served as corporate development and marketing vice-president at IDBS, chief operating officer of Singaporean biotech MerLion Pharmaceuticals, and has held research and development positions at GlaxoKlineSmith.

Molloy said: “I am very much looking forward to building and leading the team at the Medicines Discovery Catapult.

“The Catapult will engage the UK's experienced drug discovery talent and help launch a new generation of drug research and development leaders into a successful future.

“It is an incredibly exciting and forward-thinking organisation that will actively shape the direction of travel in drug discovery and development and enable others in the UK to do so too.”

2nd September 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics